OpenAI rolls out life sciences AI to speed drug discovery

OpenAI launches GPT-Rosalind, a life sciences-focused AI model designed to accelerate research in genomics and biochemistry by synthesizing evidence and generating hypotheses, while keeping humans in the loop; it features enterprise-grade security and is being rolled out in a research preview to trusted customers (e.g., Amgen, Moderna, Allen Institute, Thermo Fisher) to speed health outcomes and drug discovery without replacing scientists, amid concerns about misuse.